Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter study phase IIb randomized, blind, controlled with Placebo in search of doses to assess efficacy, safety and tolerability of two dose Subcutaneas IPP-201101 more medication of base, versus Placebo more basic medication in patients with Systemic Lupus Erythematosus (SLE).

Trial Profile

Multicenter study phase IIb randomized, blind, controlled with Placebo in search of doses to assess efficacy, safety and tolerability of two dose Subcutaneas IPP-201101 more medication of base, versus Placebo more basic medication in patients with Systemic Lupus Erythematosus (SLE).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors ImmuPharma

Most Recent Events

  • 28 Jan 2013 Results have been published in Annals of the Rheumatic Diseases according to an ImmuPharma media release.
  • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
  • 14 Nov 2012 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top